Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics has submitted a supplementary premarket approval application for its BRACAnalysis CDx test to the US Food and Drug Administration, so that it can be used to identify best responders to Pfizer's PARP inhibitor talazoparib.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.